Login to Complete an Application or to Access Judging Panel
Welcome to the 2022 Gates Grubstake Award Program
Applications for the 2022 Gates Grubstake Fund awards are now being accepted. The Gates Center for Regenerative Medicine and CU Innovations annually make multiple awards of up to $350,000 to investigators who are researching and developing in the following categories:
- Therapeutics (e.g. biologics, small molecules, gene and cell therapies)
- Diagnostics, platforms and research tools (e.g. biomaterials, scaffolds, therapeutic targets, cell expansion methods)
- Devices (e.g. drug delivery, implants, restoration)
- Cell based platforms, manufacturing and tissue engineering
Investigators are encouraged to apply if their programs fall within or even adjacent to these fields.
Interested investigators affiliated with the University of Colorado, Children’s Hospital Colorado, and the UCHealth System are encouraged to submit an application.
- Please fill out the application form online
- Please contact Heather Callahan, Heather.Callahan@cuanschutz.edu with any questions
- Applications are due by 5 pm Wednesday, August 31, 2022
- Investigators whose applications are selected for presentation will be notified in late September 2022
- Presentations to the Investment Committee are planned for November 2022
- Awardees are expected to be notified in December 2022
Read more about the Grubstake Awards
Gates Grubstake Fund 2021
- Nicholas Jacobson: "Voxel Printed Microstructures with Cells for Patient Specific Coronary Stents"
- Traci Lyons, Ph.D.: "A Novel Therapeutic for Breast Cancer"
- Michael Verneris, M.D.: "Therapeutic Development of Innate Lymphoid Cells"
- Chaitanya Puranik, B.D.S., M.S., M.Dent.Sci., Ph. D.: "Dental Filling for Regeneration of Dental Pulp"
Gates Grubstake Fund 2020
- Eduardo Davila, PhD, Professor, Division of Medical Oncology: “Manufacturing of Genetically Engineered Tumor Infiltrating Lymphocyte Therapy”
- Ulli Bayer, PhD, Professor, Department of Pharmacology: “Pharmacological Restoration of Ischemic Spinal Cord Damage”
- Michael Zuscik, PhD, Mack Clayton Professor of Orthopedics: “Abaloparatide as the First Chondroregenerative Therapy for Osteoarthritis.”
Gates Grubstake Fund 2019
- Optimized manufacturing of CD19xCd22 CAR-expressing T cells for the clinic, Terry Fry, M.D.
- Generation of functional, patient-specific thymi for cell therapy, Holger Russ, Ph.D.
- Therapeutic peptide for neuroprotection in acute closed-angle glaucoma, Ram Nagaraj, Ph.D.
- Production of efficacious recombinant hypoglycosylated FSH glycoform, T. Rajendra Kumar, Ph.D.
Gates Grubstake Fund 2018
- Prevention and treatment of pulmonary fibrosis, Ken Liechty, M.D.
- Heart regeneration by conversion of non-myocytes into functional cardiomyocytes,
Kunhua Song, Ph.D.
- Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells,
Mike Verneris, M.D.
Gates Grubstake Fund 2017
- Stem Cell-Derived Retinal Transplant to Treat Dry AMD, Maria Valeria Canto-Soler, Ph.D.
- Clinical Development of Autologous CD117+ Progenitor Cell Therapy for Solid Organ Transplantation, Martin Zamora, M.D.
- Bioresorbable 3-D Printed Personalized Implant for Cartilage Regeneration in Pediatric Growth Plate Injuries, Karin A. Payne, Ph.D.
Gates Grubstake Fund 2016
- Dr. David Wagner: A Novel Therapeutic to Impact Myelin Loss/Regeneration in Multiple Sclerosis
- Dr. Kenneth Liechty: Conjugated Nanoceria to Treat Oxidative Stress and Prevent Chronic Inflammation: First Use Treating Diabetic Ulcers
- Dr. Jeffrey Olson: Intraocular Device to Potentiate Retinal Stem Cell Transplantation in Macular Degeneration
Gates Grubstake Fund 2015
- Ganna Bilousova, Ph.D., and Igor Kogut, Ph.D.: Induced pluripotent stem cell services as a platform for clinical research
- Steven Dow, DVM, Ph.D., and Mary Ann DeGroote, M.D.: Antimicrobial stem cell therapy for infected diabetic foot ulcers
- Karin Payne, Ph.D., and Vikas Patel, M.D.: Structural living bone allografts to enhance bone formation in orthopedic surgery
Gates Grubstake Fund 2014
- Xiao-Jing Wang, M.D., Ph.D.: Human Smad7-based proteins combined with a cell-permeable peptide called Tat. Tat-Smad7 and its derivatives can be used via topical application to treat at least four diseases: oral mucositis, psoriasis, chronic wounds, and fibrotic diseases.
- Antonio Jimeno, M.D., Ph.D.: Proprietary humanized mouse model to assess cancer treatments